FNY Investment Advisers’s Novavax NVAX Stock Holding History

FNY Investment Advisers’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-136	Closed	-$1K	–	1311
2025 Q3	$1K	Buy	+136	New	+$1.06K	﹤0.01%	1162

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FNY Investment Advisers's NVAX Position: Q4 2025 in Review

FNY Investment Advisers sold out of Novavax (NVAX) in Q4 2025, closing a stake of 4,096 shares — an estimated $30.9K sold.

FNY Investment Advisers first reported a position in NVAX in Q2 2018 and held it in 5 quarters. The position peaked at $50K in Q2 2025. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2025.

FNY Investment Advisers reported no remaining Novavax position as of Q4 2025 after selling out during the quarter.
FNY Investment Advisers sold 4,096 Novavax shares in Q4 2025, an estimated $30.9K.
FNY Investment Advisers first reported a position in Novavax in Q2 2018 and held it in 5 quarters.
FNY Investment Advisers's Novavax position peaked at $50K in Q2 2025.
235 funds tracked by Wall St. Rank held Novavax as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.